1. Home
  2. APRE vs BBGI Comparison

APRE vs BBGI Comparison

Compare APRE & BBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • BBGI
  • Stock Information
  • Founded
  • APRE 2006
  • BBGI 1961
  • Country
  • APRE United States
  • BBGI United States
  • Employees
  • APRE N/A
  • BBGI N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • BBGI Broadcasting
  • Sector
  • APRE Health Care
  • BBGI Consumer Discretionary
  • Exchange
  • APRE Nasdaq
  • BBGI Nasdaq
  • Market Cap
  • APRE 9.4M
  • BBGI 8.3M
  • IPO Year
  • APRE 2019
  • BBGI 2000
  • Fundamental
  • Price
  • APRE $1.54
  • BBGI $5.33
  • Analyst Decision
  • APRE Strong Buy
  • BBGI
  • Analyst Count
  • APRE 1
  • BBGI 0
  • Target Price
  • APRE $20.00
  • BBGI N/A
  • AVG Volume (30 Days)
  • APRE 34.4K
  • BBGI 3.2K
  • Earning Date
  • APRE 11-06-2025
  • BBGI 11-04-2025
  • Dividend Yield
  • APRE N/A
  • BBGI N/A
  • EPS Growth
  • APRE N/A
  • BBGI N/A
  • EPS
  • APRE N/A
  • BBGI N/A
  • Revenue
  • APRE $841,012.00
  • BBGI $227,387,784.00
  • Revenue This Year
  • APRE N/A
  • BBGI $5.02
  • Revenue Next Year
  • APRE N/A
  • BBGI N/A
  • P/E Ratio
  • APRE N/A
  • BBGI N/A
  • Revenue Growth
  • APRE N/A
  • BBGI N/A
  • 52 Week Low
  • APRE $1.41
  • BBGI $3.67
  • 52 Week High
  • APRE $5.01
  • BBGI $14.95
  • Technical
  • Relative Strength Index (RSI)
  • APRE 43.27
  • BBGI 72.21
  • Support Level
  • APRE $1.49
  • BBGI $4.55
  • Resistance Level
  • APRE $1.66
  • BBGI $4.80
  • Average True Range (ATR)
  • APRE 0.08
  • BBGI 0.13
  • MACD
  • APRE 0.00
  • BBGI 0.06
  • Stochastic Oscillator
  • APRE 27.00
  • BBGI 93.88

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About BBGI Beasley Broadcast Group Inc.

Beasley Broadcast Group Inc is a multi-platform media company, whose primary business is operating radio stations throughout the United States. The company offers local and national advertisers integrated marketing solutions across audio, digital and event platforms. It owns and operates stations in the following markets: Atlanta, GA, Augusta, GA, Boston, MA, Charlotte, NC, Detroit, MI, Fayetteville, NC, Fort Myers-Naples, FL, Las Vegas, NV, Middlesex, NJ, Monmouth, NJ, Morristown, NJ, Philadelphia, PA, Tampa-Saint Petersburg, FL, and Wilmington, DE. The company operates in two segments Audio and Digital.

Share on Social Networks: